Compare AstraZeneca plc (AZN) vs Packaging Corporation of America (PKG) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Packaging Corporation of America (PKG) trades at $225.86, down 1.27% on the day, with a bearish technical signal but oversold RSI near support at $225. Recent Q1 2026 earnings beat expectations with EPS of $2.40, though revenue growth is modest and net income margins are projected to decline. The company announced a 20% dividend increase to $6.00 annually, signaling confidence in cash flow. Analyst consensus is mixed with a Hold rating but a $254.43 price target implies 13% upside from current levels.

Outlook is cautiously optimistic given valuation support from dividends and earnings beats, but risks include margin pressure from input costs and a negative net cash flow trend. The stock's investment case hinges on execution against Q2 guidance of $2.33 EPS and management's ability to navigate cost inflation. Near-term price action will be driven by the July 23 earnings call results.